Sanofi is abandoning plans to create its own mRNA-based coronavirus vaccine because of market-dominating drugs from competitors BioNTech-Pfizer and Moderna. Instead, Sanofi will focus on working with GlaxoSmithKline of Great Britain to bring to market another coronavirus vaccine candidate based on a protein-based approach.